This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VORNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
by Zacks Equity Research
Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.
ALNYPositive Net Change BMRNNegative Net Change NVOPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.
RDYNegative Net Change ALNYPositive Net Change GILDNegative Net Change CHRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
by Zacks Equity Research
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
ALNYPositive Net Change BMRNNegative Net Change AVXLNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Adidas AG (ADDYY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ADDYYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
by Zacks Equity Research
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
BMRNNegative Net Change CYTKPositive Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
by Zacks Equity Research
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
BMRNNegative Net Change CTMXNegative Net Change CSTLPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
by Ahan Chakraborty
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study
by Zacks Equity Research
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900.
JNJPositive Net Change BMRNNegative Net Change CSTLPositive Net Change NBTXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Best Momentum Stocks to Buy for January 21st
by Zacks Equity Research
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
ALNYPositive Net Change AVXLNegative Net Change CDNANegative Net Change
biotechnology pharmaceuticals
4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility
by Urmimala Biswas
Here are four PEG-driven value stocks, WFC, EXEL, DAL and GBX, which qualify our screening criteria.
WFCPositive Net Change DALNegative Net Change EXELNegative Net Change GBXNegative Net Change
airlines biotechnology finance medical transportation
New Strong Buy Stocks for January 21st
by Zacks Equity Research
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.
ALNYPositive Net Change AANegative Net Change ICLPositive Net Change AVXLNegative Net Change CDNANegative Net Change
biotechnology construction medical
Denali Gains 26.6% in a Year: How Should You Play the Stock?
by Zacks Equity Research
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
SNYPositive Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs pharmaceuticals
Incyte Gains 15.3% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
GSKPositive Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
by Ekta Bagri
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the sidelines at current levels.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price Cuts
by Zacks Equity Research
Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price negotiations in 2025.
BMRNNegative Net Change NVOPositive Net Change LLYPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for January 20th
by Zacks Equity Research
TV, ALLT, CMTG, PLBC and ARGX have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2025.
TVNegative Net Change ALLTNegative Net Change ARGXPositive Net Change PLBCNegative Net Change CMTGNegative Net Change
biotechnology finance reit
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
REGNPositive Net Change IONSNegative Net Change NTLANegative Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Strategic Collaborations Aid QGEN Stock Amid Competition
by Zacks Equity Research
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
OMCLPositive Net Change RMDNegative Net Change QGENNegative Net Change VCYTNegative Net Change
biotechnology medical
IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK
by Zacks Equity Research
ImmunityBio stock rises 27% on completing the regulatory filing process in the EU and the U.K. for the Anktiva/BCG combo to treat NMIBC CIS patients.
BMRNNegative Net Change CTMXNegative Net Change CSTLPositive Net Change IBRXNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
by Zacks Equity Research
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
BMRNNegative Net Change ATRANegative Net Change CTMXNegative Net Change CSTLPositive Net Change
biotechnology biotechs cell-therapy medical oncology-screening pharmaceuticals
Buy 5 Crypto-Centric Stocks Likely to Gain Big From Bitcoin Rally
by Nalak Das
Five crypto-centric stocks have strong potential for 2025. These are: NVDA, COIN, HOOD, RIOT, IBKR.
IBKRPositive Net Change NVDAPositive Net Change RIOTPositive Net Change COINNegative Net Change HOODPositive Net Change
biotechnology blockchain cryptocurrency
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
REGNPositive Net Change GSKPositive Net Change MRNANegative Net Change NTLANegative Net Change
biotechnology biotechs medical pharmaceuticals
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
by Zacks Equity Research
IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ARDS.
BMRNNegative Net Change CTMXNegative Net Change IFRXPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kymera Provides Pipeline Objectives for 2025, Stock Gains
by Zacks Equity Research
KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.
SNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals